REDWOOD CITY, CA -- (Marketwired) -- 05/20/14 -- BioCentury, EBD Group and the Biotechnology Industry Organization (BIO) will convene the 15th Annual BioEquity Europe conference in Amsterdam on Wednesday, May 21, and Thursday, May 22, at the Hilton Amsterdam Hotel. More than 500 life science investment professionals and pharmaceutical business development and licensing executives have registered. Walk-up registration is available at the Hilton Amsterdam Hotel starting at 7:45 a.m. on May 21.
BioEquity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects.
In 2014, the conference will showcase presentations by 68 mature and 42 newly formed innovator biopharma companies. The Presenting Companies have been hand-picked by BioCentury on the basis of investor validation, upcoming milestones and unpartnered assets. The slate of Next Wave Companies features fresh opportunities for venture capital investment and early stage partnering opportunities in the biotech space.
More than half a dozen plenaries and Q&A sessions over the two days will feature 45 key opinion leaders. These sessions will be highlighted by a fireside chat with Dr. Jordi Llinares-Garcia -- EMA's Head of Product Development Scientific Support Department and former Head of Orphan Drugs. During this session, BioCentury's Chairman & Editor-in-Chief Dr. Karen Bernstein will interview Dr. Llinares-Garcia about how the agency acts as an "enabler" for smaller players, including academia, in the pharmaceutical innovation ecosystem.
Back by popular demand is the BioCentury/Ernst & Young Face-Off. At the Face-Off, BioCentury will unveil its 12th annual "European Iceberg" report, which projects funding demands by Europe's clinical stage biotechnology companies, and Ernst & Young will provide analysis from its 28th annual "Beyond Borders Global Biotechnology Report." The Face-Off will be chaired by Susan Schaeffer, Editor of BioCentury, and Jürg Zürcher, Partner, EMEIA Biotechnology Leader, Ernst & Young.
Other plenaries will focus on how European biotechs can better compete with U.S. companies for capital, and how European science stands up against a global playing field.
"The full slate of presenting companies, distinguished faculty and strong pre-registration numbers indicate a renewed interest in European biotechs by the investment and licensing communities," said BioCentury Publisher Eric Pierce. "The compelling stories from the Class of 2014, coupled with high-impact discussions with our international faculty, make BioEquity Europe a must-attend event for investors and business development and licensing professionals."
See the complete program, including presenting companies, plenary schedules and a list of the 2014 faculty at http://www.biocentury.com/conferences/bioequityeurope/dates/schedule.
The 2014 BioEquity Europe Presenting Companies
Presenting companies were screened using BioCentury's industry analysis and proprietary databases, including BioCentury's BCIQ online business intelligence platform. The result is an independently selected mix of companies with proven fundraising ability, prospects for key partnerships and proximity to potentially transformational milestones.
View the complete list of presenting companies and Next Wave Presenting Companies at http://www.biocentury.com/conferences/bioequityeurope/companies/presentingcompanies.
The BioEquity Europe Sponsors & Regional Host Committee
This unique turf-neutral setting is made possible by the support of the region's life science organizations and BioEquity Europe's Sponsors. The Regional Host Committee is comprised of Amsterdam BioMed Cluster/Amsterdam Economic Board, Axon, Deloitte and Van Campen Liem.
The prestigious group of 2014 sponsors is anchored by Gold Sponsors Ernst & Young, MS Ventures and Sofinnova Partners and Silver Sponsors Abingworth, AstraZeneca, Boehringer Ingelheim Venture Fund, Edwards Wildman, Geller Biopharm, Gilde Healthcare, Index Ventures, Inserm Transfert Initiative, Johnson & Johnson Innovation, LSP-Life Sciences Partners, Oxford Finance, Piper Jaffray and Roche Venture Fund.
Since 1993, BioCentury Publications, Inc. has provided essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators and public policy makers, and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, television, data products and collaborative industry conferences in the U.S., Europe and Asia.
BioEquity Europe is one of three annual investor conferences organized by BioCentury. The next conference, NewsMakers in the Biotech Industry, will take place on Sept. 26, 2014, followed by Future Leaders in the Biotech Industry, on March 20, 2015. Both events will take place at the Millennium Broadway Hotel & Conference Center in New York City.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group's conferences are run with the support of leading corporations and international trade associations and include:
EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
About the Biotechnology Industry Organization
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.